Englander Institute for Precision Medicine

Class IA PI3Ks regulate subcellular and functional dynamics of IDO1.

TitleClass IA PI3Ks regulate subcellular and functional dynamics of IDO1.
Publication TypeJournal Article
Year of Publication2020
AuthorsIacono A, Pompa A, De Marchis F, Panfili E, Greco FA, Coletti A, Orabona C, Volpi C, Belladonna ML, Mondanelli G, Albini E, Vacca C, Gargaro M, Fallarino F, Bianchi R, Lousa CDe Marcos, Mazza EMc, Bicciato S, Proietti E, Milano F, Martelli MP, Iamandii IM, Garcia-Mila MGraupera, Sopena JLlena, Hawkins P, Suire S, Okkenhaug K, Stark A-K, Grassi F, Bellucci M, Puccetti P, Santambrogio L, Macchiarulo A, Grohmann U, Pallotta MT
JournalEMBO Rep
Volume21
Issue12
Paginatione49756
Date Published2020 Dec 03
ISSN1469-3178
KeywordsDendritic Cells, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase, Inflammation, Phosphatidylinositol 3-Kinases, Signal Transduction
Abstract

Knowledge of a protein's spatial dynamics at the subcellular level is key to understanding its function(s), interactions, and associated intracellular events. Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytosolic enzyme that controls immune responses via tryptophan metabolism, mainly through its enzymic activity. When phosphorylated, however, IDO1 acts as a signaling molecule in plasmacytoid dendritic cells (pDCs), thus activating genomic effects, ultimately leading to long-lasting immunosuppression. Whether the two activities-namely, the catalytic and signaling functions-are spatially segregated has been unclear. We found that, under conditions favoring signaling rather than catabolic events, IDO1 shifts from the cytosol to early endosomes. The event requires interaction with class IA phosphoinositide 3-kinases (PI3Ks), which become activated, resulting in full expression of the immunoregulatory phenotype in vivo in pDCs as resulting from IDO1-dependent signaling events. Thus, IDO1's spatial dynamics meet the needs for short-acting as well as durable mechanisms of immune suppression, both under acute and chronic inflammatory conditions. These data expand the theoretical basis for an IDO1-centered therapy in inflammation and autoimmunity.

DOI10.15252/embr.201949756
Alternate JournalEMBO Rep
PubMed ID33159421
PubMed Central IDPMC7726814

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021